These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 3805718

  • 1. Terminal complement components play a role in the expression of C5a.
    Gresham HD, Renfer L, Hammer CH, Frank MM.
    J Immunol; 1987 Feb 01; 138(3):838-41. PubMed ID: 3805718
    [Abstract] [Full Text] [Related]

  • 2. Freeze-thaw activation of the complement attack phase: II. Comparison of convertase generated C--56 with C--56 generated by freezing and thawing.
    Dessauer A, Rother U, Rother K.
    Acta Pathol Microbiol Immunol Scand Suppl; 1984 Feb 01; 284():83-8. PubMed ID: 6444196
    [Abstract] [Full Text] [Related]

  • 3. The release of C5a in complement-activated serum does not require C6.
    Biesecker G, Wagner JL, Hugli TE.
    J Immunol; 1989 Aug 15; 143(4):1228-32. PubMed ID: 2545783
    [Abstract] [Full Text] [Related]

  • 4. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
    Hammer CH, Hänsch G, Gresham HD, Shin ML.
    J Immunol; 1983 Aug 15; 131(2):892-8. PubMed ID: 6863934
    [Abstract] [Full Text] [Related]

  • 5. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA, Goldman RC, Hammer CH, Leive L, Frank MM.
    J Immunol; 1983 Nov 15; 131(5):2570-5. PubMed ID: 6355297
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H, Tsuboi M, Nagaki K.
    Immunology; 1986 Jul 15; 58(3):459-65. PubMed ID: 3733147
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
    Hetland G, Bungum L.
    APMIS; 1988 Jan 15; 96(1):89-92. PubMed ID: 3345254
    [Abstract] [Full Text] [Related]

  • 11. Cytotoxic action and other metabolic consequences of terminal complement proteins.
    Shin ML, Carney DF.
    Prog Allergy; 1988 Jan 15; 40():44-81. PubMed ID: 3281171
    [No Abstract] [Full Text] [Related]

  • 12. Secretion of the terminal complement proteins, C5-C9, by human platelets.
    Houle JJ, Leddy JP, Rosenfeld SI.
    Clin Immunol Immunopathol; 1989 Mar 15; 50(3):385-93. PubMed ID: 2917425
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cleavage of the fifth component of complement and generation of a functionally active C5b6-like complex by human leukocyte elastase.
    Vogt W.
    Immunobiology; 2000 Jan 15; 201(3-4):470-7. PubMed ID: 10776801
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs.
    Rollins SA, Matis LA, Springhorn JP, Setter E, Wolff DW.
    Transplantation; 1995 Dec 15; 60(11):1284-92. PubMed ID: 8525523
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.